Eli Lilly reports promising lung cancer drug results (LLY:NYSE)
· seekingalpha.com
Lilly’s olomorasib showed promising lung cancer trial results, boosting its KRAS G12C treatment outlook ahead of key Phase 3 data.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...